In an earlier work of our study group, we assessed the diagnostic value of CXCR4-directed PET/CT compared to the performance to reference standard [18F]fluorodesoxyglucose (FDG) PET/CT in patients with NEC. This evidence concerns the gene CXCR4 and neuroendocrine carcinoma.